Saturday 17 October 2026
Export SPRY’s income statement to Excel — free account
ARS Pharmaceuticals, Inc.
SPRY Healthcare Biotechnology
ARS Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $84.3 million, down 5.46% from fiscal 2024. In the quarter to June 2026, revenue grew 114.2%, EPS fell 37.0%, free cash flow fell 53.7% and total debt rose 138.5%, each against the same quarter a year earlier.
4.02
0.05
−1.23%
Follow SPRY
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
6.96 | 13.63 | 8.06 | 6.80 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(21.11) | (26.41) | (17.74) | (13.06) | |
P/B ratio |
6.73 | 10.05 | 13.01 | 63.58 | |
Price to Tangible BV |
7.47 | 11.51 | 16.92 | 0.00 | |
EV/Sales |
6.12 | 12.72 | 7.76 | 7.05 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(10.23) | (6.28) | (4.39) | (4.19) | |
EV/FCF |
(10.16) | (5.75) | (4.03) | (3.88) | |
Quick Ratio |
6.38 | 6.91 | 4.63 | 3.13 | |
Current Ratio |
6.66 | 7.28 | 4.94 | 3.48 | |
Net Debt/EBITDA |
2.23 | 1.82 | 0.49 | (0.45) | |
Debt/Assets |
45.14% | 51.43% | 59.53% | 68.78% | |
Debt/Equity |
1.14 | 1.47 | 2.79 | 13.72 | |
Asset Turnover |
0.48 | 0.25 | 0.32 | 0.42 | |
Operating CF/Net income |
0.92 | 1.05 | 0.74 | 0.98 | |
Capex/Depreciation |
8.64 | 3.41 | 0.00 | 0.00 | |
Interest Coverage |
— | — | (24.64) | (24.79) | |
Research and Development Expense of Revenue |
8.46% | 12.26% | 19.12% | 13.96% | |
Selling, General and Administrative Expense of Revenue |
230.00% | 213.46% | 318.35% | 230.49% | |
Intangible Assets out of Total Assets |
0.04 | 0.04 | 0.05 | 0.06 | |
Share Based Compensation of Revenue |
17.50% | 20.43% | 32.73% | 36.83% | |
Graham Net Nets |
0.11 | 0.06 | 0.02 | (0.03) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(8.06%) | (15.02%) | (25.03%) | (27.22%) | |
Free Cash Flow Yield |
(8.66%) | (16.25%) | (23.93%) | (26.66%) | |
Revenue per Share |
0.33 | 0.29 | 0.23 | 0.34 | |
Operating CF per Share |
(0.48) | (0.44) | (0.45) | (0.61) | |
Capex per Share |
(0.06) | (0.02) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.54) | (0.46) | (0.45) | (0.61) | |
Cash per Share |
2.92 | 2.49 | 2.02 | 1.45 | |
Shareholders Equity per Share |
1.49 | 1.16 | 0.62 | 0.13 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.49 | 1.16 | 0.62 | 0.13 | |
Free Cash Flow |
(53.10) | (45.48) | (44.95) | (60.93) | |
Working Capital |
287.99 | 245.75 | 195.62 | 150.65 | |
Capital Expenditures |
(6.06) | (2.00) | — | — | |
Net Current Asset Value |
113.72 | 71.50 | 18.97 | (25.47) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.19 | 0.07 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
18.61 | 16.76 | 18.98 | 35.98 | |
Average Payables |
33.14 | 30.39 | 37.64 | 52.00 | |
Average Inventory |
4.25 | 6.79 | 8.04 | 10.21 | |
Average Assets |
295.20 | 339.40 | 307.44 | 281.48 | |
Average Common Equity |
174.32 | 185.53 | 145.14 | 102.42 |
Columns are period end dates